The ongoing investigations of CVS Caremark and the so-called “pay-for-delay” agreements between brand name and generic drug manufacturers appear to be high priorities for the U.S. Federal Trade Commission, based on Chairman Jon Leibowitz’s recent testimony on Capitol Hill.
Continue reading ‘CVS Caremark Investigation, Pay-for-Delay Deals Top FTC Agenda’
